Olema Pharmaceuticals, Inc.

NasdaqGS:OLMA Stock Report

Market Cap: US$549.6m

Olema Pharmaceuticals Future Growth

Future criteria checks 0/6

Olema Pharmaceuticals is forecast to grow earnings and revenue by 8.1% and 67.2% per annum respectively. EPS is expected to grow by 15.9% per annum. Return on equity is forecast to be -64.9% in 3 years.

Key information

8.1%

Earnings growth rate

15.9%

EPS growth rate

Biotechs earnings growth21.3%
Revenue growth rate67.2%
Future return on equity-64.9%
Analyst coverage

Good

Last updated18 Apr 2024

Recent future growth updates

Recent updates

Palazestrant's Journey: Olema Pharmaceuticals' Long Oncology Path

Mar 28

Estimating The Fair Value Of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

Mar 04
Estimating The Fair Value Of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

Here's Why We're Not Too Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation

Nov 09
Here's Why We're Not Too Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation

We're Keeping An Eye On Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate

Jun 11
We're Keeping An Eye On Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate

Will Olema Pharmaceuticals (NASDAQ:OLMA) Spend Its Cash Wisely?

Mar 01
Will Olema Pharmaceuticals (NASDAQ:OLMA) Spend Its Cash Wisely?

Olema Oncology grants stock options for 58.3K shares

Oct 05

We're Not Very Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate

Sep 13
We're Not Very Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate

Olema Pharmaceuticals GAAP EPS of -$0.82 misses by $0.18

Aug 09

Olema stock soars 12% as FDA grants fast track status to OP-1250 for breast cancer subtype

Jul 21

We Think Olema Pharmaceuticals (NASDAQ:OLMA) Can Easily Afford To Drive Business Growth

May 29
We Think Olema Pharmaceuticals (NASDAQ:OLMA) Can Easily Afford To Drive Business Growth

Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth

Feb 08
Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth

Our Take On Olema Pharmaceuticals

Jan 05

We're Not Very Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate

Sep 19
We're Not Very Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate

We Think Olema Pharmaceuticals (NASDAQ:OLMA) Can Afford To Drive Business Growth

Jun 04
We Think Olema Pharmaceuticals (NASDAQ:OLMA) Can Afford To Drive Business Growth

Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth

Feb 19
Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth

Earnings and Revenue Growth Forecasts

NasdaqGS:OLMA - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20268-177-144N/A6
12/31/2025N/A-163-130-1427
12/31/2024N/A-134-119-1178
12/31/2023N/A-97-84-84N/A
9/30/2023N/A-96-85-85N/A
6/30/2023N/A-97-81-80N/A
3/31/2023N/A-110-85-85N/A
12/31/2022N/A-105-82-82N/A
9/30/2022N/A-100-82-81N/A
6/30/2022N/A-95-76-75N/A
3/31/2022N/A-79-59-58N/A
12/31/2021N/A-71-52-51N/A
9/30/2021N/A-60-42-41N/A
6/30/2021N/A-52-37-37N/A
3/31/2021N/A-38-29-29N/A
12/31/2020N/A-24-20-20N/A
9/30/2020N/A-15-12-12N/A
12/31/2019N/A-4-3-3N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: OLMA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: OLMA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: OLMA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: OLMA is forecast to have no revenue next year.

High Growth Revenue: OLMA is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: OLMA is forecast to be unprofitable in 3 years.


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.